Hepatitis A IgM

If you have yellowing skin, dark urine, nausea, or unexplained liver enzyme elevations, the question your doctor needs to answer is what is causing it. This test answers one specific version of that question: is hepatitis A virus the reason?

HAV IgM (hepatitis A immunoglobulin M) is the antibody your immune system produces in the first days of a hepatitis A infection. A positive result tells you that you have an acute or very recent infection. A negative result essentially rules hepatitis A out as the cause of your current symptoms.

What This Antibody Actually Reflects

Hepatitis A virus is spread through contaminated food, water, or close contact with an infected person. When the virus enters your body, your immune system mounts a response, and specialized white blood cells (plasma cells and plasmablasts, the antibody-producing factories of the immune system) start producing IgM antibodies aimed at the virus.

These antibodies typically become detectable in your blood 5 to 10 days before symptoms begin, are present at the time symptoms start, and then peak within the first month of illness before declining over the following months. Most people clear them within 6 months, though in one observational study a meaningful minority of patients remained positive beyond 200 days.

Because the antibody is so tightly tied to recent infection, a positive result is the standard way to diagnose acute hepatitis A. The virus itself cannot be distinguished from other viral hepatitis causes based on symptoms alone.

Acute Hepatitis A Infection

A positive HAV IgM result means you have an acute hepatitis A infection in progress or one that recently resolved. The infection typically comes with markedly elevated liver enzymes (ALT levels often exceeding 1,000 IU/L in confirmed cases), elevated bilirubin, and jaundice in more than 70 percent of confirmed acute cases in adults. Fever, malaise, and dark urine are common.

Hepatitis A is almost always self-limited. Liver enzymes and bilirubin typically return to normal within 2 to 3 months after illness onset, and chronic infection does not occur. Knowing the cause changes what happens next: you can stop chasing other diagnoses, alert close contacts, and avoid further workup of more serious liver conditions.

Rare but Serious Complications

A small fraction of acute hepatitis A cases progress to fulminant hepatitis, where the liver fails rapidly. Elevated serum creatinine has been identified as a predictor of poor outcome in HAV-associated acute liver failure. In studies of patients with hepatitis A-related acute liver failure, transplant-free survival has been reported in the range of roughly 60 to 70 percent, depending on the cohort.

Pregnancy may raise the stakes. Some studies of acute hepatitis A during pregnancy have reported increased rates of preterm contractions, placental separation, premature rupture of membranes, and preterm delivery, while other clinical guidance notes that infection has not consistently been shown to affect maternal or fetal outcomes. A confirmed diagnosis during pregnancy generally prompts closer prenatal monitoring.

How This Differs From Total Hepatitis A Antibody Testing

A separate test, total anti-HAV (which measures both IgM and IgG), reflects all hepatitis A antibodies combined. That test answers a different question: am I immune to hepatitis A, either from past infection or vaccination? A positive total antibody result with a negative IgM means you are immune but do not have an active infection.

This distinction matters. IgM is for diagnosing a current infection in someone who feels sick. Total antibody is for checking immunity in someone who feels fine. Confusing the two leads to either missed diagnoses or unnecessary vaccinations.

When Results Can Be Misleading

The most important pitfall with this test is the high rate of false positives when used in the wrong setting. When tested in people without symptoms in a population where acute hepatitis A is uncommon, the positive predictive value drops sharply. One review found that the majority of positive results in outpatient settings were ordered in patients with chronic liver disease rather than acute illness, and only a small fraction of patients with positive results actually had acute hepatitis A.

• Low-level positive results: borderline positive readings (low signal-to-cutoff values) frequently turn out to be false positives. One study found that confirmed acute cases had much higher signal-to-cutoff values than samples that turned out to have alternative diagnoses.
• Recent hepatitis A vaccination: IgM anti-HAV can be detectable 2 to 3 weeks after vaccination in roughly 8 to 20 percent of adults, creating a false-positive window if the test is run soon after a shot.
• Biotin supplements: high-dose biotin (used for hair, skin, and nails) can interfere with some assay platforms. In laboratory testing of the HAV IgM assay specifically, biotin caused a small rate of false negatives; the false-positive effect from biotin has been documented for the total anti-HAV assay rather than the IgM-specific assay.
• Possible cross-reactivity with other viral infections: in patients with acute Epstein-Barr virus, cytomegalovirus, or hepatitis E infections, polyclonal antibody activation can occasionally produce nonspecific reactivity on viral IgM assays. Most of the published cross-reactivity evidence involves hepatitis E IgM testing rather than HAV IgM specifically, but it is one reason a positive result with an inconsistent clinical picture warrants confirmation.

Because of these issues, current guidelines from the Infectious Diseases Society of America and the Advisory Committee on Immunization Practices recommend testing only people with symptoms suspicious for acute hepatitis. When a result is positive but the clinical picture does not fit (no jaundice, only mild enzyme elevation, no exposure history), confirmation with hepatitis A RNA testing by nucleic acid amplification is the next step.

One Reading Is Usually Enough

Unlike cholesterol or glucose, this is not a biomarker you track over time. A single positive result during an episode of acute hepatitis confirms the diagnosis. A single negative result in a sick person essentially rules hepatitis A out (sensitivity is very high in symptomatic patients).

The one situation where repeat testing makes sense is when the first result is equivocal or weakly positive. In that case, repeat testing a week or two later, paired with a hepatitis A RNA test, helps separate a true acute infection from a false-positive blip. Once you have had hepatitis A and recovered, you do not need to retest IgM. You will likely be immune for life, which can be confirmed with a one-time total antibody check if you ever need documentation.

What an Unexpected Positive Result Should Trigger

If your IgM comes back positive and you have symptoms and elevated liver enzymes consistent with acute hepatitis, the diagnosis is essentially settled. The next steps focus on supportive care, monitoring for the rare complication of fulminant liver failure, and notifying public health authorities. Close contacts should be assessed for vaccination or immune globulin.

If your IgM is positive but you feel fine, your liver enzymes are normal, and you have no exposure history, treat the result with skepticism. Order a hepatitis A RNA test to confirm whether actual virus is present. Review whether you have been vaccinated recently or taken high-dose biotin. Consider whether another acute viral infection could be contributing to a nonspecific antibody response. A specialist in infectious disease or hepatology is worth involving if the picture remains unclear after this workup.

Companion tests that almost always belong with this one in any acute hepatitis workup include a full liver panel (ALT, AST, bilirubin, alkaline phosphatase, GGT), tests for the other major viral hepatitis causes (hepatitis B surface antigen, hepatitis B core IgM, hepatitis C antibody, hepatitis E IgM), and basic markers of liver function (prothrombin time, albumin). A creatinine check is useful because elevated creatinine is a warning sign for severe disease.